Trial reportHuman reproduction (Oxford, England)2004
Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy.
Trial report in Human reproduction (Oxford, England), 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06064669 (Effect of Metformin on Healthy Live Birth After In-vitro Fertilization in Women With Prediabetes Mellitus), which is not on this map. Cited by 41 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Metformin on Healthy Live Birth After In-vitro Fertilization in Women With Prediabetes Mellitus: a Multicenter Double-blind Placebo Controlled Randomized Trial
Who cites it
41 citing papers in PubMed, 7 syntheses or guidelines pooled it, 253 citations in OpenAlex.
- Systematic review and meta-analysis of birth outcomes in women with polycystic ovary syndrome.Nature communications · 2024Pooled it
- Systematic review and meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome.Nature communications · 2024Pooled it
- Oral anti-diabetic agents for women with established diabetes/impaired glucose tolerance or previous gestational diabetes planning pregnancy, or pregnant women with pre-existing diabetes.The Cochrane database of systematic reviews · 2017 · on this mapPooled it
- Comparison of glyburide with metformin in treating gestational diabetes mellitus: a systematic review and meta-analysis.Clinical drug investigation · 2015Pooled it
- Efficacy and safety of oral antidiabetic drugs in comparison to insulin in treating gestational diabetes mellitus: a meta-analysis.PloS one · 2014Pooled it
- Metformin vs insulin in the management of gestational diabetes: a meta-analysis.PloS one · 2013 · on this mapPooled it
- Oral anti-diabetic agents for women with pre-existing diabetes mellitus/impaired glucose tolerance or previous gestational diabetes mellitus.The Cochrane database of systematic reviews · 2010Pooled it
- Metformin treatment in type 2 diabetes in pregnancy: an active controlled, parallel-group, randomized, open label study in patients with type 2 diabetes in pregnancy.Journal of diabetes research · 2015 · on this mapTrial
- Predictors of small-for-gestational-age infants in gestational diabetes mellitus: the impact of metformin use.Archives of gynecology and obstetrics · 2025Article
- Long-term effects of metformin on offspring health: A review of current evidence and future directions.Diabetes, obesity & metabolism · 2025Review
- Placental Mitochondrial Function and Dysfunction in Preeclampsia.International journal of molecular sciences · 2023Review
- Early Treatment with Metformin Improves Neurological Outcomes in Lafora Disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023Article
- Article
- PGC-1α activity and mitochondrial dysfunction in preterm infants.Frontiers in physiology · 2022Review
- Molecular docking and mouse modeling suggest CMKLR1 and INSR as targets for improving PCOS phenotypes by minocycline.EXCLI journal · 2022Article
- Metformin effects on zonulin level in polycystic ovarian women.ADMET & DMPK · 2021Article
- Article
- The Effects of Maternal Metformin Treatment on Late Prenatal and Early Postnatal Development of the Offspring Are Modulated by Sex.Pharmaceuticals (Basel, Switzerland) · 2020Article
- Metformin during Pregnancy: Effects on Offspring Development and Metabolic Function.Frontiers in pharmacology · 2020Review
- Current Researches, Rationale, Plausibility, and Evidence Gaps on Metformin for the Management of Hypertensive Disorders of Pregnancy.Frontiers in pharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe prospectively assessed growth and motor-social development during the first 18 months of life in 126 live births (122 pregnancies) to 109 women with polycystic ovary syndrome (PCOS) who conceived on and continued metformin (1.5-2.55 g/day) through pregnancy.
methodsThe lengths and weights of PCOS neonates were compared with gender-specific Centers for Disease Control and Prevention (CDC) infant data. Gestational diabetes (GD) and pre-eclampsia in women with PCOS were compared with 252 healthy women without PCOS who had >or=1 live birth (262 live births).
resultsThere were 101 out of 126 (80%) term (>or=37 gestational weeks) PCOS births, which was not significantly different (P = 0.7) from controls, 206 out of 252 (81.7%). There were two (1.6%) birth defects. GD occurred in nine out of 119 PCOS pregnancies (7.6%) versus 40 out of 251 (15.9%) controls, P = 0.027. The prevalence of pre-eclampsia did not differ in PCOS versus control pregnancies (4.1 versus 3.6%, P = 0.8). The birth length and weight of the 52 male neonates did not differ (P > 0.05) from those of CDC males; the 74 female neonates were shorter than CDC females (48.9 +/- 5.4 versus 50.6 +/- 2.7 cm, P = 0.006) and weighed less (3.09 +/- 0.85 versus 3.29 +/- 0.52 kg, P = 0.04). There were no systematic differences in growth between PCOS and CDC infants over 18 months. At 3, 6, 9, 12 and 18 months, of a potential 100% motor-social development score, scores (+/-SD) were 95 +/- 13, 98 +/- 8%, 95 +/- 10, 97 +/- 8 and 94 +/- 16%; no infants had motor-social developmental delays.
conclusionsMetformin reduced development of GD, was not teratogenic and did not adversely affect birth length and weight, growth or motor-social development in the first 18 months of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.